Hengrui Medicine completes ESOP transfers, unlocks 2022 plan, advances drug trial

Jiangsu Hengrui Medicine announced the completion of an off-market transfer of 13,511,100 A-shares into its 2025 A-share employee stock ownership plan (ESOP) account on November 6, 2025. This transfer, priced at RMB 30.95 per share, represents 0.20% of the company's total share capital. The 2025 A-share ESOP's first holder meeting was held on November 7, 2025, establishing a management committee to oversee its operations.

Separately, the company announced that the third lock-up period for its 2022 employee stock ownership plan ended on November 7, 2025. This plan, which received an off-market transfer of 12,000,000 A-shares at RMB 4.97 per share on November 4, 2022, has met its 100% unlocking conditions. This includes cumulative innovative drug sales revenue exceeding RMB 320 billion, over 33 new molecular entity IND approvals, and more than 21 NDA applications with received acceptance for 2022-2024. A total of 860 employees are eligible to unlock 2,830,300 shares, representing 0.04% of the company’s total share capital.

Additionally, Jiangsu Hengrui Medicine received approval from the National Medical Products Administration for the clinical trial of SHR-4610 injection, an innovative anti-tumor drug, for advanced solid tumors. The company has invested approximately RMB 73.6 million in this project.